Fundraising FoxHaima
2 known investors
Find your way into Haima
Sign up to see every warm intro you have to Haima
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Haima team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
Founders & leadership
AS
Anirban Sen GuptaCTO
MB
MN
Matthew NealCMO
CP
Christa PawlowskiCOO and EVP of R&D
TP
Timothy PeluraExecutive Chair
Investors · 2
Related companies · 1
Companies working in the same space as Haima.
Frequently asked questions
- What does Haima do?
- Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders. Its lead technology, SynthoPlate, is a fully-synthetic hemostatic agent that acts at the injury site to amplify the body's natural clotting mechanisms.
- Who founded Haima?
- Haima was founded by Anirban Sen Gupta.
- Who are Haima's investors?
- Haima's investors include CWRU Technology Ventures, Tachyon Ventures.